Company Overview
Snapshot
Founded in February 2017 by David Bassa, Stero Biotechs operates with 1–10 employees. The company has secured $1 million in total capital raised across one funding round. In January 2021, Stero Biotechs supported an exploratory study for CBD-based treatment for severe COVID-19 patients.
Business overview
Stero Biotechs is a clinical-stage company focused on researching and developing novel treatment solutions that utilize cannabidiol (CBD), a non-psychotropic component of cannabis sativa. The company's core technology leverages CBD's immunomodulatory and anti-inflammatory properties to reduce the side effects and necessity of steroid therapy. Stero Biotechs serves the healthcare and life sciences markets, specifically within the pharmaceutical sector, with a focus on autoimmune and inflammatory diseases.
Strategic signal
In January 2021, Stero Biotechs supported an exploratory study of CBD-based treatment for severe COVID-19 patients at Rabin Medical Center. This initiative highlights the company's strategic agility in applying its core CBD research to emerging global health crises, demonstrating potential for broader therapeutic applications beyond its initial focus on autoimmune and inflammatory conditions. This signals to investors a proactive approach to product development and market relevance.
Log in to access full profile ›Company Intelligence Q&A
- What is Stero Biotechs' primary focus?
- Stero Biotechs is a clinical-stage company dedicated to researching and developing novel CBD-based treatment solutions aimed at reducing the side effects and need for steroid therapy in patients.
- When did Stero Biotechs begin clinical trials for COVID-19 treatment?
- In January 2021, Stero Biotechs supported an exploratory study of CBD-based treatment for severe COVID-19 patients at Rabin Medical Center. This followed earlier announcements in April and May 2020 regarding clinical trials for COVID-19 patients using CBD-steroid treatment.
- What was the outcome of the proposed acquisition by Kalytera Therapeutics?
- In April 2020, Kalytera Therapeutics Inc. announced that it would not proceed with the previously planned acquisition of Stero Biotechs, which had been detailed in March 2020 for an estimated $30 million.
- Has Stero Biotechs conducted clinical trials for Crohn's disease?
- Yes, in July 2019, Stero Biotechs announced it would commence a Phase 2a clinical trial for a cannabidiol-based formulation for patients with steroid-dependent Crohn's disease, with the aim of lowering steroid dosage.
- When did Stero Biotechs secure a patent for CBD as a steroid-sparing treatment?
- In August 2018, STERO Biotechs Ltd. secured a U.S. patent for a steroid-sparing Cannabidiol (CBD)-based treatment for autoimmune and chronic inflammatory diseases, with clinical trials set to begin in October 2018.